In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Sky News presenter Jacquie Beltrao has lived in her stylish home in south-west London for 12 years with her husband Eduardo ...

Data shows Norway, which is similar in population size to NZ, increased its five-year survival rates for ovarian cancer from 34.1% to 46.1% in the almost two decades from 1995. In contrast, New ...

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

Sky presenter Jacquie Beltrao opens up about the milestone 60th she wondered if she'd reach, how husband Eduardo has been her ...

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

EXCLUSIVE: Sky presenter Jacquie Beltrao invites OK! into her home as she opens up exclusively about the milestone 60th she ...

Shuttle Pharma seeks US patent for PSMA Ligand Conjugates to treat prostate cancer: Gaithersburg, Maryland Monday, April 14, 2025, 16:00 Hrs [IST] Shuttle Pharmaceuticals Holdings ...